Pfenex believes it and commercial partner Alvogen could benefit from an extended period as the only direct competition to Eli Lilly’s Forteo (teriparatide) osteoporosis blockbuster in the US. However, Alvogen has not yet launched the hybrid 505(b)(2) drug as the partners are waiting for the US Food and Drug Administration to decide whether to designate the PF708 candidate, which the agency approved in early October under the Bonsity brand name, as therapeutically equivalent, or ‘A-rated’, to Forteo.
Informing investors that he expected Alvogen to launch Bonsity upon receiving the agency’s therapeutic equivalence decision, Pfenex’ CEO Eef Schimmelpennink...



